Clinical Trial Update: Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations [Phase 1, Phase 2]

View source ↗

Summary

A study of TPX-0046, a RET/SRC inhibitor, in adults with advanced solid tumors including non-small cell lung cancer and medullary thyroid carcinoma was terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• TPX-0046 (TPX-0046)

Snippet

Sponsor: Turning Point Therapeutics, Inc. | Conditions: Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-06-13